Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023" report has been added to ResearchAndMarkets.com's offering. This...
COM701 in combination with nivolumab ± BMS-986207 (anti-TIGIT) in heavily pretreated patient population, resulted in encouraging durable confirmed partial...
Market factors and a company announcement helped the stock climb.
At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 (anti-TIGIT) demonstrated encouraging 20% overall response rate and 40% disease control...
At the time of abstract data cutoff, COM701+ nivolumab + BMS-986207 demonstrated encouraging 20% overall response rate and 40% disease control rate in heavily pretreated patients with platinum...